Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236285 | 0.95 | NOTUM (0.38) | NOTUMSMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL2233683 | 0.89 | KDM4E (0.41) | TSHRMEN1KMT2A | |
| SCHEMBL2237173 | 0.89 | KDM4E (0.35) | — | |
| SCHEMBL2234012 | 0.89 | BUB1 (0.33) | — | |
| SCHEMBL2234009 | 0.89 | BUB1 (0.33) | — | |
| SCHEMBL2233990 | 0.88 | — | — | |
| SCHEMBL2234001 | 0.88 | — | — | |
| SCHEMBL2234658 | 0.88 | PDK1 (0.36) | NOTUMSMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL2355410 | 0.88 | DTYMK (0.33) | MEN1KMT2A | |
| SCHEMBL2235353 | 0.88 | GABRA1 (0.35) | NOTUMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | NOTUM 547/4885SMN1; SMN2 4075/4885TSHR 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.